Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects
Information source: Ludwig-Maximilians - University of Munich
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: IBZM-SPECT (bolus and constant infusion paradigm) (Procedure)
Phase: N/A
Status: Completed
Sponsored by: Ludwig-Maximilians - University of Munich Official(s) and/or principal investigator(s):
Oliver Pogarell, MD, Principal Investigator, Affiliation: Dept. of Psychiatry, University of Munich
Klaus Tatsch, MD, Principal Investigator, Affiliation: Dept. of Nuclear Medicine, University of Munich
Summary
This study is an investigation of the dopaminergic neurotransmission in patients with
schizophrenia, patients at risk for the development of schizophrenia, and healthy controls
using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging
technique under amphetamine challenge.
Clinical Details
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Primary outcome: dopamine receptor availability
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical diagnosis of schizophrenia (currently unmedicated)
- Subjects at risk for the development of schizophrenia (prodromal symptoms)
- Healthy subjects
- Written informed consent
Exclusion Criteria:
- Neurological or severe somatic disorders
- Women during pregnancy or lactation
- Occupational exposition to radiation > 15mSv
- Medication known to interfere with IBZM
- Contraindications for the use of amphetamine challenge
Locations and Contacts
Dept. of Nuclear Medicine, Munich D-81377, Germany
Dept. of Psychiatry, Munich D-80336, Germany
Additional Information
Starting date: January 2004
Last updated: May 6, 2008
|
